What is HC Wainwright’s Forecast for BioLineRx Q3 Earnings?

BioLineRx Ltd. (NASDAQ:BLRX) – Equities researchers at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for BioLineRx in a research note issued on Thursday, August 14th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings of ($0.41) per share for the quarter, up from their prior estimate of ($0.43). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for BioLineRx’s current full-year earnings is ($5.80) per share. HC Wainwright also issued estimates for BioLineRx’s Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($0.63) EPS.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Thursday, August 14th. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.65). The business had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.66 million. BioLineRx had a negative return on equity of 54.79% and a negative net margin of 45.34%.

Several other brokerages have also issued reports on BLRX. Jones Trading raised BioLineRx from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 30th. Wall Street Zen raised BioLineRx to a “sell” rating in a research note on Saturday, July 12th.

BioLineRx Price Performance

BioLineRx stock opened at $3.71 on Monday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.04 and a current ratio of 2.27. The firm has a market cap of $15.80 million, a P/E ratio of -0.42 and a beta of 1.15. The business’s fifty day moving average is $4.41 and its two-hundred day moving average is $3.72. BioLineRx has a 52 week low of $2.30 and a 52 week high of $32.26.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.